{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:28:16Z","timestamp":1790857696988,"version":"4.1.0"},"publisher-location":"Cham","reference-count":138,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031084904","type":"print"},{"value":"9783031084911","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-3-031-08491-1_16","type":"book-chapter","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T19:02:55Z","timestamp":1666119775000},"page":"425-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["How to Manage Pseudomonas aeruginosa Infections"],"prefix":"10.1007","author":[{"given":"Matthaios","family":"Papadimitriou-Olivgeris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Guery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"16_CR1","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1128\/aac.01799-09","volume":"54","author":"C Antachopoulos","year":"2010","unstructured":"Antachopoulos C, Karvanen M, Iosifidis E et al (2010) Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob Agents Chemother 54:3985\u20133987. https:\/\/doi.org\/10.1128\/aac.01799-09","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR2","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/antibiotics9080500","volume":"9","author":"RM Antonello","year":"2020","unstructured":"Antonello RM, Principe L, Maraolo AE et al (2020) Fosfomycin as partner drug for systemic infection management. A systematic review of its synergistic properties from in vitro and in vivo studies. Antibiotics 9:500. https:\/\/doi.org\/10.3390\/antibiotics9080500","journal-title":"Antibiotics"},{"key":"16_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1586\/14787210.5.3.507","volume":"5","author":"M Aoun","year":"2014","unstructured":"Aoun M (2014) Empiric therapy for febrile neutropenia: what are the choices? Expert Rev Anti Infect Ther 5:507\u2013515. https:\/\/doi.org\/10.1586\/14787210.5.3.507","journal-title":"Expert Rev Anti Infect Ther"},{"key":"16_CR4","unstructured":"Armaganidis A, Zakynthinos S, Mandragos C (2017) Efficacy of murepavadin coadministered with standard of care in a phase 2 study in patients with ventilator-associated pneumonia due to suspected or documented Pseudomonas aeruginosa infections. In: 37th International symposium intensive care emergency medicine, ISICEM, Brussels, Belgium"},{"key":"16_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s2213-2600(18)30345-x","volume":"7","author":"E Azoulay","year":"2019","unstructured":"Azoulay E, Mokart D, Kouatchet A et al (2019) Acute respiratory failure in immunocompromised adults. Lancet Respir Med 7:1\u201314. https:\/\/doi.org\/10.1016\/s2213-2600(18)30345-x","journal-title":"Lancet Respir Med"},{"key":"16_CR6","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1093\/cid\/ciz668","volume":"70","author":"T Babich","year":"2019","unstructured":"Babich T, Naucler P, Valik JK et al (2019) Ceftazidime, carbapenems, or piperacillin-tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection \u2013 a multi-site retrospective study. Clin Infect Dis 70:2270\u20132280. https:\/\/doi.org\/10.1093\/cid\/ciz668","journal-title":"Clin Infect Dis"},{"key":"16_CR7","doi-asserted-by":"publisher","unstructured":"Babich T, Naucler P, Valik JK et al (2021) Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study. J Antimicrob Chemother. https:\/\/doi.org\/10.1093\/jac\/dkab134","DOI":"10.1093\/jac\/dkab134"},{"key":"16_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14787210.2017.1251840","volume":"15","author":"M Bassetti","year":"2017","unstructured":"Bassetti M, Carnelutti A, Peghin M (2017) Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in Gram-negative bacterial infections. Expert Rev Anti Infect Ther 15:55\u201365. https:\/\/doi.org\/10.1080\/14787210.2017.1251840","journal-title":"Expert Rev Anti Infect Ther"},{"key":"16_CR9","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212527","volume":"7","author":"M Bassetti","year":"2018","unstructured":"Bassetti M, Vena A, Croxatto A et al (2018) How to manage Pseudomonas aeruginosa infections. Drugs Context 7:212527. https:\/\/doi.org\/10.7573\/dic.212527","journal-title":"Drugs Context"},{"key":"16_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/s1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21:226\u2013240. https:\/\/doi.org\/10.1016\/s1473-3099(20)30796-9","journal-title":"Lancet Infect Dis"},{"key":"16_CR11","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1128\/aac.02365-12","volume":"57","author":"KA Bauer","year":"2013","unstructured":"Bauer KA, West JE, O\u2019Brien JM, Goff DA (2013) Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 57:2907\u20132912. https:\/\/doi.org\/10.1128\/aac.02365-12","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR12","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/cid\/ciw684","volume":"63","author":"YD Benattar","year":"2016","unstructured":"Benattar YD, Omar M, Zusman O et al (2016) The effectiveness and safety of high-dose colistin: prospective cohort study. Clin Infect Dis 63:1605\u20131612. https:\/\/doi.org\/10.1093\/cid\/ciw684","journal-title":"Clin Infect Dis"},{"key":"16_CR13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12890-016-0339-5","volume":"16","author":"AY Bhagirath","year":"2016","unstructured":"Bhagirath AY, Li Y, Somayajula D et al (2016) Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med 16:174. https:\/\/doi.org\/10.1186\/s12890-016-0339-5","journal-title":"BMC Pulm Med"},{"key":"16_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/cid\/ciy543","volume":"36","author":"A Bonell","year":"2018","unstructured":"Bonell A, Azarrafiy R, Huong VTL et al (2018) A systematic review and meta-analysis of ventilator associated pneumonia in adults in Asia; an analysis of national income level on incidence and etiology. Clin Infect Dis 36:627. https:\/\/doi.org\/10.1093\/cid\/ciy543","journal-title":"Clin Infect Dis"},{"key":"16_CR15","doi-asserted-by":"publisher","first-page":"e0073921","DOI":"10.1128\/aac.00739-21","volume":"65","author":"J Bruss","year":"2021","unstructured":"Bruss J, Lister T, Gupta VK et al (2021) Single- and multiple-ascending-dose study of the safety, tolerability, and pharmacokinetics of the polymyxin derivative SPR206. Antimicrob Agents Chemother 65:e0073921. https:\/\/doi.org\/10.1128\/aac.00739-21","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.medcli.2018.04.020","volume":"152","author":"A Callejas-D\u00edaz","year":"2018","unstructured":"Callejas-D\u00edaz A, Fern\u00e1ndez-P\u00e9rez C, Ramos-Mart\u00ednez A et al (2018) Impact of Pseudomonas aeruginosa bacteraemia in a tertiary hospital: mortality and prognostic factors. Med Clin 152:83\u201389. https:\/\/doi.org\/10.1016\/j.medcli.2018.04.020","journal-title":"Med Clin"},{"key":"16_CR17","doi-asserted-by":"publisher","unstructured":"Camus L, Vandenesch F, Moreau K (2021) From genotype to phenotype: adaptations of Pseudomonas aeruginosa to the cystic fibrosis environment. Microb Genom 7. https:\/\/doi.org\/10.1099\/mgen.0.000513","DOI":"10.1099\/mgen.0.000513"},{"key":"16_CR18","doi-asserted-by":"publisher","first-page":"e00567-17","DOI":"10.1128\/aac.00567-17","volume":"61","author":"M Castanheira","year":"2017","unstructured":"Castanheira M, Huband MD, Mendes RE, Flamm RK (2017) Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother 61:e00567-17. https:\/\/doi.org\/10.1128\/aac.00567-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"16_CR19","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.1086\/321854","volume":"33","author":"WA Craig","year":"2001","unstructured":"Craig WA (2001) Does the dose matter? Clin Infect Dis 33(Suppl 3):S233\u2013S237. https:\/\/doi.org\/10.1086\/321854","journal-title":"Clin Infect Dis"},{"key":"16_CR20","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1128\/aac.01183-09","volume":"54","author":"JL Crandon","year":"2010","unstructured":"Crandon JL, Bulik CC, Kuti JL, Nicolau DP (2010) Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 54:1111\u20131116. https:\/\/doi.org\/10.1128\/aac.01183-09","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR21","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/cid\/ciw726","volume":"64","author":"LM Daniels","year":"2017","unstructured":"Daniels LM, Juliano J, Marx A, Weber DJ (2017) Inhaled antibiotics for hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis 64:386\u2013387. https:\/\/doi.org\/10.1093\/cid\/ciw726","journal-title":"Clin Infect Dis"},{"key":"16_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106196","volume":"56","author":"E del Barrio-Tofi\u00f1o","year":"2020","unstructured":"del Barrio-Tofi\u00f1o E, Causap\u00e9 CL, Oliver A (2020) Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired \u03b2-lactamases: 2020 update. Int J Antimicrob Ag 56:106196. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106196","journal-title":"Int J Antimicrob Ag"},{"key":"16_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3109\/00365548.2011.616221","volume":"44","author":"A Dinh","year":"2011","unstructured":"Dinh A, Salomon J, Bru JP, Bernard L (2011) Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis 44:182\u2013189. https:\/\/doi.org\/10.3109\/00365548.2011.616221","journal-title":"Scand J Infect Dis"},{"key":"16_CR24","doi-asserted-by":"publisher","first-page":"S565","DOI":"10.1093\/cid\/ciz830","volume":"69","author":"Y Doi","year":"2019","unstructured":"Doi Y (2019) Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis 69:S565\u2013S575. https:\/\/doi.org\/10.1093\/cid\/ciz830","journal-title":"Clin Infect Dis"},{"key":"16_CR25","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1164\/rccm.201505-0857oc","volume":"192","author":"JM Dulhunty","year":"2015","unstructured":"Dulhunty JM, Roberts JA, Davis JS et al (2015) A multicenter randomized trial of continuous versus intermittent \u03b2-lactam infusion in severe sepsis. Am J Resp Crit Care 192:1298\u20131305. https:\/\/doi.org\/10.1164\/rccm.201505-0857oc","journal-title":"Am J Resp Crit Care"},{"key":"16_CR26","volume-title":"WHO Regional Office for Europe and European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe, 2020 data. Executive summary","author":"ECDC, WHO","year":"2021","unstructured":"ECDC, WHO (2021) WHO Regional Office for Europe and European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe, 2020 data. Executive summary. WHO Regional Office for Europe, Copenhagen. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Surveillance-antimicrobial-resistance-in-Europe-2020.pdf"},{"key":"16_CR27","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1093\/jac\/dkq285","volume":"65","author":"LS Elias","year":"2010","unstructured":"Elias LS, Konzen D, Krebs JM, Zavascki AP (2010) The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 65:2231\u20132237. https:\/\/doi.org\/10.1093\/jac\/dkq285","journal-title":"J Antimicrob Chemother"},{"key":"16_CR28","unstructured":"European-Medicines-Agency (2020a) Recommendations to restrict use of fosfomycin antibiotics. https:\/\/www.ema.europa.eu\/"},{"key":"16_CR29","unstructured":"European-Medicines-Agency (2020b) Fetcroja: EU summary of product characteristics. https:\/\/www.ema.europa.eu\/"},{"key":"16_CR30","unstructured":"European-Medicines-Agency (2020c) Vaborem: EU summary of product characteristics. https:\/\/www.ema.europa.eu\/"},{"key":"16_CR31","unstructured":"European-Medicines-Agency (2020d) Recarbrio: EU summary of product characteristics. https:\/\/www.ema.europa.eu\/"},{"key":"16_CR32","unstructured":"European-Medicines-Agency (2020e) Withdrawal of application for the marketing authorisation of Zemdri (plazomicin). https:\/\/www.ema.europa.eu\/"},{"key":"16_CR33","unstructured":"European-Medicines-Agency (2021a) Zebraxa: EU summary of product characteristics. https:\/\/www.ema.europa.eu\/"},{"key":"16_CR34","unstructured":"European-Medicines-Agency (2021b) Zavicefta: EU summary of product characteristics. https:\/\/www.ema.europa.eu\/"},{"key":"16_CR35","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/ccm.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med 49:e1063\u2013e1143. https:\/\/doi.org\/10.1097\/ccm.0000000000005337","journal-title":"Crit Care Med"},{"key":"16_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijantimicag.2006.08.024","volume":"29","author":"ME Falagas","year":"2007","unstructured":"Falagas ME, Bliziotis IA, Tam VH (2007) Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Ag 29:9\u201325. https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.08.024","journal-title":"Int J Antimicrob Ag"},{"key":"16_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/antibiotics10010079","volume":"10","author":"M Fiore","year":"2021","unstructured":"Fiore M, Corrente A, Pace MC et al (2021) Ceftolozane-tazobactam combination therapy compared to ceftolozane-tazobactam monotherapy for the treatment of severe infections: a systematic review and meta-analysis. Antibiotics 10:79. https:\/\/doi.org\/10.3390\/antibiotics10010079","journal-title":"Antibiotics"},{"issue":"4","key":"16_CR38","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR (2011) Infectious diseases society of America. Clin Infect Dis 52(4):e56\u2013e93. https:\/\/doi.org\/10.1093\/cid\/cir073","journal-title":"Clin Infect Dis"},{"key":"16_CR39","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1097\/01.ccm.0000275389.31974.22","volume":"35","author":"J Garnacho-Montero","year":"2007","unstructured":"Garnacho-Montero J, Sa-Borges M, Sol\u00e9-Viol\u00e1n J et al (2007) Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 35:1888\u20131895. https:\/\/doi.org\/10.1097\/01.ccm.0000275389.31974.22","journal-title":"Crit Care Med"},{"key":"16_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14787210.2018.1447381","volume":"16","author":"DR Giacobbe","year":"2018","unstructured":"Giacobbe DR, Bassetti M, Rosa FGD et al (2018) Ceftolozane\/tazobactam: place in therapy. Expert Rev Anti Infect Ther 16:307\u2013320. https:\/\/doi.org\/10.1080\/14787210.2018.1447381","journal-title":"Expert Rev Anti Infect Ther"},{"key":"16_CR41","doi-asserted-by":"publisher","first-page":"e01350-17","DOI":"10.1128\/aac.01350-17","volume":"61","author":"KJ Goodlet","year":"2017","unstructured":"Goodlet KJ, Nicolau DP, Nailor MD (2017) In vitro comparison of ceftolozane-tazobactam to traditional beta-lactams and ceftolozane-tazobactam as an alternative to combination antimicrobial therapy for Pseudomonas aeruginosa. Antimicrob Agents Chemother 61:e01350-17. https:\/\/doi.org\/10.1128\/aac.01350-17","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR42","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cmi.2016.12.005","volume":"23","author":"B Grabein","year":"2017","unstructured":"Grabein B, Graninger W, Ba\u00f1o JR et al (2017) Intravenous fosfomycin\u2014back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect 23:363\u2013372. https:\/\/doi.org\/10.1016\/j.cmi.2016.12.005","journal-title":"Clin Microbiol Infect"},{"key":"16_CR43","unstructured":"Griffith D (2019) Qpex biopharma product pipeline; pharma pipeline updates: Part II. S163. In: ASM microbe, San Francisco, CA"},{"key":"16_CR44","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1128\/aac.01015-06","volume":"51","author":"RY Hachem","year":"2007","unstructured":"Hachem RY, Chemaly RF, Ahmar CA et al (2007) Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 51:1905\u20131911. https:\/\/doi.org\/10.1128\/aac.01015-06","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-micro-102215-095308","volume":"70","author":"JC Henderson","year":"2015","unstructured":"Henderson JC, Zimmerman SM, Crofts AA et al (2015) The power of asymmetry: architecture and assembly of the Gram-negative outer membrane lipid bilayer. Annu Rev Microbiol 70:1\u201324. https:\/\/doi.org\/10.1146\/annurev-micro-102215-095308","journal-title":"Annu Rev Microbiol"},{"key":"16_CR46","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ijantimicag.2016.08.020","volume":"48","author":"JP Horcajada","year":"2016","unstructured":"Horcajada JP, Sorl\u00ed L, Luque S et al (2016) Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate. Int J Antimicrob Ag 48:725\u2013727. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.08.020","journal-title":"Int J Antimicrob Ag"},{"key":"16_CR47","doi-asserted-by":"publisher","unstructured":"Horcajada JP, Montero M, Oliver A et al (2019) Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 32. https:\/\/doi.org\/10.1128\/cmr.00031-19","DOI":"10.1128\/cmr.00031-19"},{"key":"16_CR48","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ijantimicag.2013.09.002","volume":"42","author":"Y Hu","year":"2013","unstructured":"Hu Y, Li L, Li W et al (2013) Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies. Int J Antimicrob Ag 42:492\u2013496. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.09.002","journal-title":"Int J Antimicrob Ag"},{"key":"16_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3109\/00365548.2014.956791","volume":"47","author":"R Huttunen","year":"2015","unstructured":"Huttunen R, \u00c5ttman E, Aittoniemi J et al (2015) Nosocomial bloodstream infections in a Finnish tertiary care hospital: a retrospective cohort study of 2175 episodes during the years 1999\u20132001 and 2005\u20132010. Infect Dis 47:20\u201326. https:\/\/doi.org\/10.3109\/00365548.2014.956791","journal-title":"Infect Dis"},{"key":"16_CR50","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/jac\/dkv402","volume":"71","author":"A Ito","year":"2016","unstructured":"Ito A, Kohira N, Bouchillon SK et al (2016a) In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother 71:670\u2013677. https:\/\/doi.org\/10.1093\/jac\/dkv402","journal-title":"J Antimicrob Chemother"},{"key":"16_CR51","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.1128\/aac.01405-16","volume":"60","author":"A Ito","year":"2016","unstructured":"Ito A, Nishikawa T, Matsumoto S et al (2016b) Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:7396\u20137401. https:\/\/doi.org\/10.1128\/aac.01405-16","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR52","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.3390\/ijms22063128","volume":"22","author":"I Jurado-Mart\u00edn","year":"2021","unstructured":"Jurado-Mart\u00edn I, Sainz-Mej\u00edas M, McClean S (2021) Pseudomonas aeruginosa: an audacious pathogen with an adaptable arsenal of virulence factors. Int J Mol Sci 22:3128. https:\/\/doi.org\/10.3390\/ijms22063128","journal-title":"Int J Mol Sci"},{"key":"16_CR53","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M et al (2016) Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63:e61\u2013e111. https:\/\/doi.org\/10.1093\/cid\/ciw353","journal-title":"Clin Infect Dis"},{"key":"16_CR54","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1469-0691.2005.01102.x","volume":"11","author":"C Kang","year":"2005","unstructured":"Kang C, Kim S, Park W et al (2005) Clinical features and outcome of patients with community-acquired Pseudomonas aeruginosa bacteraemia. Clin Microbiol Infect 11:415\u2013418","journal-title":"Clin Microbiol Infect"},{"key":"16_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17425255.2017.1230200","volume":"13","author":"I Karaiskos","year":"2016","unstructured":"Karaiskos I, Souli M, Galani I, Giamarellou H (2016) Colistin: still a lifesaver for the 21st century? Expert Opin Drug Met 13:1\u201313. https:\/\/doi.org\/10.1080\/17425255.2017.1230200","journal-title":"Expert Opin Drug Met"},{"key":"16_CR56","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/jac\/dkz401","volume":"75","author":"S Karakonstantis","year":"2019","unstructured":"Karakonstantis S, Kritsotakis EI, Gikas A (2019) Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. J Antimicrob Chemother 75:271\u2013282. https:\/\/doi.org\/10.1093\/jac\/dkz401","journal-title":"J Antimicrob Chemother"},{"key":"16_CR57","doi-asserted-by":"publisher","first-page":"e00472-17","DOI":"10.1128\/aac.00472-17","volume":"61","author":"JA Karlowsky","year":"2017","unstructured":"Karlowsky JA, Kazmierczak KM, BLM d J et al (2017) In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother 61:e00472-17. https:\/\/doi.org\/10.1128\/aac.00472-17","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR58","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1128\/AAC.43.3.623","volume":"43","author":"AD Kashuba","year":"1999","unstructured":"Kashuba AD, Nafziger AN, Drusano GL, Bertino JS (1999) Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother 43:623\u2013629","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR59","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ijantimicag.2018.09.008","volume":"52","author":"T Khawcharoenporn","year":"2018","unstructured":"Khawcharoenporn T, Chuncharunee A, Maluangnon C et al (2018) Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia. Int J Antimicrob Ag 52:828\u2013834. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.09.008","journal-title":"Int J Antimicrob Ag"},{"key":"16_CR60","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1097\/ccm.0b013e3181eb3ccd","volume":"38","author":"A Kumar","year":"2010","unstructured":"Kumar A, Zarychanski R, Light B et al (2010) Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 38:1773\u20131785. https:\/\/doi.org\/10.1097\/ccm.0b013e3181eb3ccd","journal-title":"Crit Care Med"},{"key":"16_CR61","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1093\/cid\/civ536","volume":"61","author":"MK Lacy","year":"2015","unstructured":"Lacy MK, Stryjewski ME, Wang W et al (2015) Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality. Clin Infect Dis 61:S87\u2013S93. https:\/\/doi.org\/10.1093\/cid\/civ536","journal-title":"Clin Infect Dis"},{"key":"16_CR62","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s11908-015-0493-6","volume":"17","author":"SY Liang","year":"2015","unstructured":"Liang SY, Kumar A (2015) Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance. Curr Infect Dis Rep 17:493. https:\/\/doi.org\/10.1007\/s11908-015-0493-6","journal-title":"Curr Infect Dis Rep"},{"key":"16_CR63","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/jac\/dkx438","volume":"73","author":"DM Livermore","year":"2017","unstructured":"Livermore DM, Meunier D, Hopkins KL et al (2017a) Activity of ceftazidime\/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015\u201316. J Antimicrob Chemother 73:648\u2013657. https:\/\/doi.org\/10.1093\/jac\/dkx438","journal-title":"J Antimicrob Chemother"},{"key":"16_CR64","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/jac\/dkx360","volume":"73","author":"DM Livermore","year":"2017","unstructured":"Livermore DM, Mushtaq S, Warner M et al (2017b) Potential of high-dose cefepime\/tazobactam against multiresistant Gram-negative pathogens. J Antimicrob Chemother 73:126\u2013133. https:\/\/doi.org\/10.1093\/jac\/dkx360","journal-title":"J Antimicrob Chemother"},{"key":"16_CR65","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1086\/510590","volume":"44","author":"TP Lodise","year":"2007","unstructured":"Lodise TP, Lomaestro B, Drusano GL (2007) Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44:357\u2013363. https:\/\/doi.org\/10.1086\/510590","journal-title":"Clin Infect Dis"},{"key":"16_CR66","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1128\/aac.00633-16","volume":"60","author":"C Lucasti","year":"2016","unstructured":"Lucasti C, Vasile L, Sandesc D et al (2016) Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother 60:6234\u20136243. https:\/\/doi.org\/10.1128\/aac.00633-16","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR67","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jhin.2014.05.007","volume":"87","author":"A Lucena","year":"2014","unstructured":"Lucena A, Costa LMD, Nogueira KS et al (2014) Nosocomial infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: molecular epidemiology, risk factors, clinical features and outcomes. J Hosp Infect 87:234\u2013240. https:\/\/doi.org\/10.1016\/j.jhin.2014.05.007","journal-title":"J Hosp Infect"},{"key":"16_CR68","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/17476348.2016.1177460","volume":"10","author":"H Lund-Palau","year":"2016","unstructured":"Lund-Palau H, Turnbull AR, Bush A et al (2016) Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches. Expert Rev Respir Med 10:685\u2013697. https:\/\/doi.org\/10.1080\/17476348.2016.1177460","journal-title":"Expert Rev Respir Med"},{"key":"16_CR69","doi-asserted-by":"publisher","unstructured":"Magiorakos AP, Srinivasan A, Carey RB et al (2011) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"16_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105891","volume":"55","author":"AE Maraolo","year":"2020","unstructured":"Maraolo AE, Mazzitelli M, Trecarichi EM et al (2020) Ceftolozane\/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: a systematic review about its efficacy and safety for off-label indications. Int J Antimicrob Ag 55:105891. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105891","journal-title":"Int J Antimicrob Ag"},{"key":"16_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhin.2016.11.014","volume":"95","author":"KL McCarthy","year":"2017","unstructured":"McCarthy KL, Paterson DL (2017) Long-term mortality following Pseudomonas aeruginosa bloodstream infection. J Hosp Infect 95:1\u20138. https:\/\/doi.org\/10.1016\/j.jhin.2016.11.014","journal-title":"J Hosp Infect"},{"issue":"1","key":"16_CR72","first-page":"78","volume":"31","author":"J Mensa","year":"2018","unstructured":"Mensa J, Barber\u00e1n J, Soriano A et al (2018) Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: guidelines by the Spanish Society of Chemotherapy. Rev Esp Quimioter 31(1):78\u2013100","journal-title":"Rev Esp Quimioter"},{"key":"16_CR73","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581st","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC et al (2019) Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Resp Crit Care 200:e45\u2013e67. https:\/\/doi.org\/10.1164\/rccm.201908-1581st","journal-title":"Am J Resp Crit Care"},{"key":"16_CR74","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13054-015-0926-5","volume":"19","author":"ST Micek","year":"2015","unstructured":"Micek ST, Wunderink RG, Kollef MH et al (2015) An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care 19:219. https:\/\/doi.org\/10.1186\/s13054-015-0926-5","journal-title":"Crit Care"},{"key":"16_CR75","doi-asserted-by":"publisher","first-page":"e02596-17","DOI":"10.1128\/aac.02596-17","volume":"62","author":"ML Monogue","year":"2018","unstructured":"Monogue ML, Giovagnoli S, Bissantz C et al (2018) In vivo efficacy of meropenem with a novel non-\u03b2-lactam\u2013\u03b2-lactamase inhibitor, nacubactam, against Gram-negative organisms exhibiting various resistance mechanisms in a murine complicated urinary tract infection model. Antimicrob Agents Chemother 62:e02596-17. https:\/\/doi.org\/10.1128\/aac.02596-17","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR76","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s15010-009-8342-x","volume":"37","author":"M Montero","year":"2009","unstructured":"Montero M, Horcajada JP, Sorl\u00ed L et al (2009) Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 37:461\u2013465. https:\/\/doi.org\/10.1007\/s15010-009-8342-x","journal-title":"Infection"},{"key":"16_CR77","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","volume":"155","author":"RD Moore","year":"1987","unstructured":"Moore RD, Lietman PS, Smith CR (1987) Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155:93\u201399. https:\/\/doi.org\/10.1093\/infdis\/155.1.93","journal-title":"J Infect Dis"},{"key":"16_CR78","doi-asserted-by":"publisher","first-page":"e00514-19","DOI":"10.1128\/aac.00514-19","volume":"63","author":"I Morrissey","year":"2019","unstructured":"Morrissey I, Magnet S, Hawser S et al (2019) In vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from U.S. and European hospitals during 2014\u20132015. Antimicrob Agents Chemother 63:e00514-19. https:\/\/doi.org\/10.1128\/aac.00514-19","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR79","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1128\/aac.00296-10","volume":"54","author":"B Moy\u00e1","year":"2010","unstructured":"Moy\u00e1 B, Zamorano L, Juan C et al (2010) Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother 54:3933\u20133937. https:\/\/doi.org\/10.1128\/aac.00296-10","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR80","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40265-018-0880-z","volume":"78","author":"AE Muller","year":"2018","unstructured":"Muller AE, Huttner B, Huttner A (2018) Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections? Drugs 78:439\u2013451. https:\/\/doi.org\/10.1007\/s40265-018-0880-z","journal-title":"Drugs"},{"key":"16_CR81","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/cid\/ciu213","volume":"59","author":"RL Nation","year":"2014","unstructured":"Nation RL, Velkov T, Li J (2014) Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 59:88\u201394. https:\/\/doi.org\/10.1093\/cid\/ciu213","journal-title":"Clin Infect Dis"},{"key":"16_CR82","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/s1473-3099(19)30574-2","volume":"20","author":"MS Niederman","year":"2019","unstructured":"Niederman MS, Alder J, Bassetti M et al (2019) Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. Lancet Infect Dis 20:330\u2013340. https:\/\/doi.org\/10.1016\/s1473-3099(19)30574-2","journal-title":"Lancet Infect Dis"},{"key":"16_CR83","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.drup.2015.08.002","volume":"21\u201322","author":"A Oliver","year":"2015","unstructured":"Oliver A, Mulet X, Lopez-Causape C, Juan C (2015) The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updat 21\u201322:41\u201359. https:\/\/doi.org\/10.1016\/j.drup.2015.08.002","journal-title":"Drug Resist Updat"},{"key":"16_CR84","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ijantimicag.2019.08.025","volume":"54","author":"L Onorato","year":"2019","unstructured":"Onorato L, Caprio GD, Signoriello S, Coppola N (2019) Efficacy of ceftazidime\/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis. Int J Antimicrob Ag 54:735\u2013740. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.08.025","journal-title":"Int J Antimicrob Ag"},{"key":"16_CR85","doi-asserted-by":"publisher","unstructured":"Paul M, Yahav D, Bivas A et al (2010) Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Db Syst Rev:CD005197. https:\/\/doi.org\/10.1002\/14651858.cd005197.pub3","DOI":"10.1002\/14651858.cd005197.pub3"},{"key":"16_CR86","doi-asserted-by":"publisher","unstructured":"Paul M, Carrara E, Retamar P et al (2021) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by ESICM \u2013 European Society of intensive care Medicine). Clin Microbiol Infect. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025","DOI":"10.1016\/j.cmi.2021.11.025"},{"key":"16_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10096-017-2907-x","volume":"36","author":"M Paulsson","year":"2017","unstructured":"Paulsson M, Granrot A, Ahl J et al (2017) Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study. Eur J Clin Microbiol 36:1\u201310. https:\/\/doi.org\/10.1007\/s10096-017-2907-x","journal-title":"Eur J Clin Microbiol"},{"key":"16_CR88","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.ajic.2014.08.006","volume":"42","author":"Y Peng","year":"2014","unstructured":"Peng Y, Bi J, Shi J et al (2014) Multidrug-resistant Pseudomonas aeruginosa infections pose growing threat to health care-associated infection control in the hospitals of Southern China: a case-control surveillance study. Am J Infect Control 42:1308\u20131311. https:\/\/doi.org\/10.1016\/j.ajic.2014.08.006","journal-title":"Am J Infect Control"},{"key":"16_CR89","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s10096-019-03573-4","volume":"38","author":"B Pilmis","year":"2019","unstructured":"Pilmis B, Petitjean G, Lesprit P et al (2019) Continuous infusion of ceftolozane\/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa. Eur J Clin Microbiol 38:1457\u20131461. https:\/\/doi.org\/10.1007\/s10096-019-03573-4","journal-title":"Eur J Clin Microbiol"},{"key":"16_CR90","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1128\/cmr.00064-16","volume":"30","author":"L Poirel","year":"2017","unstructured":"Poirel L, Jayol A, Nordmann P (2017) Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev 30:557\u2013596. https:\/\/doi.org\/10.1128\/cmr.00064-16","journal-title":"Clin Microbiol Rev"},{"key":"16_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth S, van Veenhuyzen D, Echols R et al (2018) Articles cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 18:1\u201310. https:\/\/doi.org\/10.1016\/s1473-3099(18)30554-1","journal-title":"Lancet Infect Dis"},{"key":"16_CR92","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ijantimicag.2015.03.001","volume":"45","author":"A Potron","year":"2015","unstructured":"Potron A, Poirel L, Nordmann P (2015) Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Ag 45:568\u2013585. https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.03.001","journal-title":"Int J Antimicrob Ag"},{"key":"16_CR93","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1186\/1471-2334-13-561","volume":"13","author":"AA Quartin","year":"2013","unstructured":"Quartin AA, Scerpella EG, Puttagunta S, Kett DH (2013) A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study. BMC Infect Dis 13:561. https:\/\/doi.org\/10.1186\/1471-2334-13-561","journal-title":"BMC Infect Dis"},{"key":"16_CR94","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13756-018-0370-9","volume":"7","author":"G Raman","year":"2018","unstructured":"Raman G, Avendano EE, Chan J et al (2018) Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist In 7:79. https:\/\/doi.org\/10.1186\/s13756-018-0370-9","journal-title":"Antimicrob Resist In"},{"key":"16_CR95","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijantimicag.2018.03.018","volume":"52","author":"R Recio","year":"2018","unstructured":"Recio R, Villa J, Viedma E et al (2018) Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: facing the perfect storm. Int J Antimicrob Ag 52:172\u2013179. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.03.018","journal-title":"Int J Antimicrob Ag"},{"key":"16_CR96","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s00134-005-2691-4","volume":"31","author":"R Reina","year":"2005","unstructured":"Reina R, Estenssoro E, S\u00e1enz G et al (2005) Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31:1058\u20131065. https:\/\/doi.org\/10.1007\/s00134-005-2691-4","journal-title":"Intensive Care Med"},{"key":"16_CR97","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cmi.2017.04.011","volume":"23","author":"J Rello","year":"2017","unstructured":"Rello J, Sol\u00e9-Lleonart C, Rouby J-J et al (2017) Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect 23:629\u2013639. https:\/\/doi.org\/10.1016\/j.cmi.2017.04.011","journal-title":"Clin Microbiol Infect"},{"key":"16_CR98","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1093\/jac\/dkv281","volume":"70","author":"A Ribera","year":"2015","unstructured":"Ribera A, Benavent E, Lora-Tamayo J et al (2015) Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus \u03b2-lactams. J Antimicrob Chemother 70:3357\u20133365. https:\/\/doi.org\/10.1093\/jac\/dkv281","journal-title":"J Antimicrob Chemother"},{"key":"16_CR99","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s15010-019-01352-z","volume":"47","author":"DC Richter","year":"2019","unstructured":"Richter DC, Frey O, R\u00f6hr A et al (2019) Therapeutic drug monitoring-guided continuous infusion of piperacillin\/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience. Infection 47:1001\u20131011. https:\/\/doi.org\/10.1007\/s15010-019-01352-z","journal-title":"Infection"},{"key":"16_CR100","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1097\/ccm.0b013e3181a0054d","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Webb S, Paterson D et al (2009) A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 37:2071\u20132078. https:\/\/doi.org\/10.1097\/ccm.0b013e3181a0054d","journal-title":"Crit Care Med"},{"key":"16_CR101","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/s1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J et al (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14:498\u2013509. https:\/\/doi.org\/10.1016\/s1473-3099(14)70036-2","journal-title":"Lancet Infect Dis"},{"key":"16_CR102","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/jac\/dkz069","volume":"74","author":"JA Roberts","year":"2019","unstructured":"Roberts JA, Alobaid AS, Wallis SC et al (2019) Defining optimal dosing of ciprofloxacin in patients with septic shock. J Antimicrob Chemother 74:1662\u20131669. https:\/\/doi.org\/10.1093\/jac\/dkz069","journal-title":"J Antimicrob Chemother"},{"key":"16_CR103","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1097\/aln.0b013e3182755d7a","volume":"117","author":"J-J Rouby","year":"2012","unstructured":"Rouby J-J, Bouhemad B, Monsel A et al (2012) Aerosolized antibiotics for ventilator-associated pneumonia. Anesthesiology 117:1364\u20131380. https:\/\/doi.org\/10.1097\/aln.0b013e3182755d7a","journal-title":"Anesthesiology"},{"key":"16_CR104","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1093\/jac\/dky227","volume":"73","author":"HS Sader","year":"2018","unstructured":"Sader HS, Flamm RK, Dale GE et al (2018) Murepavadin activity tested against contemporary (2016\u201317) clinical isolates of XDR Pseudomonas aeruginosa. J Antimicrob Chemother 73:2400\u20132404. https:\/\/doi.org\/10.1093\/jac\/dky227","journal-title":"J Antimicrob Chemother"},{"key":"16_CR105","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3947\/ic.2021.0051","volume":"53","author":"S Sahra","year":"2021","unstructured":"Sahra S, Jahangir A, Hamadi R et al (2021) Clinical and microbiologic efficacy and safety of imipenem\/cilastatin\/relebactam in complicated infections: a meta-analysis. Infect Chemother 53:271\u2013283. https:\/\/doi.org\/10.3947\/ic.2021.0051","journal-title":"Infect Chemother"},{"key":"16_CR106","doi-asserted-by":"publisher","first-page":"e00533-18","DOI":"10.1128\/aac.00533-18","volume":"62","author":"SM Schmidt-Malan","year":"2018","unstructured":"Schmidt-Malan SM, Mishra AJ, Mushtaq A et al (2018) In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant Gram-negative bacilli. Antimicrob Agents Chemother 62:e00533-18. https:\/\/doi.org\/10.1128\/aac.00533-18","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkx139","volume":"72","author":"M Sims","year":"2017","unstructured":"Sims M, Mariyanovski V, McLeroth P et al (2017) Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother 72:1\u201311. https:\/\/doi.org\/10.1093\/jac\/dkx139","journal-title":"J Antimicrob Chemother"},{"key":"16_CR108","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s10096-014-2125-8","volume":"33","author":"C Slekovec","year":"2014","unstructured":"Slekovec C, Robert J, Trystram D et al (2014) Pseudomonas aeruginosa in French hospitals between 2001 and 2011: back to susceptibility. Eur J Clin Microbiol 33:1713\u20131717. https:\/\/doi.org\/10.1007\/s10096-014-2125-8","journal-title":"Eur J Clin Microbiol"},{"key":"16_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/1321487","volume":"2016","author":"MC Sonmezer","year":"2016","unstructured":"Sonmezer MC, Ertem G, Erdinc FS et al (2016) Evaluation of risk factors for antibiotic resistance in patients with nosocomial infections caused by Pseudomonas aeruginosa. Can J Infect Dis Medical Microbiol 2016:1\u20139. https:\/\/doi.org\/10.1155\/2016\/1321487","journal-title":"Can J Infect Dis Medical Microbiol"},{"issue":"4","key":"16_CR110","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","volume":"10","author":"A Soriano","year":"2021","unstructured":"Soriano A, Carmeli Y, Omrani AS et al (2021) Ceftazidime-avibactam for the treatment of serious Gram-negative infections with limited treatment options: a systematic literature review. Infect Dis Ther 10(4):1989\u20132034. https:\/\/doi.org\/10.1007\/s40121-021-00507-6","journal-title":"Infect Dis Ther"},{"key":"16_CR111","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/1471-2334-13-380","volume":"13","author":"L Sorl\u00ed","year":"2013","unstructured":"Sorl\u00ed L, Luque S, Grau S et al (2013) Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 13:380. https:\/\/doi.org\/10.1186\/1471-2334-13-380","journal-title":"BMC Infect Dis"},{"key":"16_CR112","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12879-016-2117-7","volume":"17","author":"L Sorl\u00ed","year":"2017","unstructured":"Sorl\u00ed L, Luque S, Segura C et al (2017) Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa. BMC Infect Dis 17:11. https:\/\/doi.org\/10.1186\/s12879-016-2117-7","journal-title":"BMC Infect Dis"},{"key":"16_CR113","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/jpids\/piz002","volume":"8","author":"PD Tamma","year":"2019","unstructured":"Tamma PD, Hsu AJ (2019) Defining the role of novel \u03b2-lactam agents that target carbapenem-resistant Gram-negative organisms. J Pediatric Infect Dis Soc 8:251\u2013260. https:\/\/doi.org\/10.1093\/jpids\/piz002","journal-title":"J Pediatric Infect Dis Soc"},{"key":"16_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2018.5727","volume":"15","author":"S Tang","year":"2018","unstructured":"Tang S, Zhang S, Wu J et al (2018) Comparison of mono- and combination antibiotic therapy for the treatment of Pseudomonas aeruginosa bacteraemia: a cumulative meta-analysis of cohort studies. Exp Ther Med 15:1\u201311. https:\/\/doi.org\/10.3892\/etm.2018.5727","journal-title":"Exp Ther Med"},{"key":"16_CR115","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1128\/aac.42.3.521","volume":"42","author":"JK Thomas","year":"1998","unstructured":"Thomas JK, Forrest A, Bhavnani SM et al (1998) Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 42:521\u2013527. https:\/\/doi.org\/10.1128\/aac.42.3.521","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR116","doi-asserted-by":"publisher","unstructured":"Titov I, Wunderink RG, Roquilly A et al (2020) A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study). Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa803","DOI":"10.1093\/cid\/ciaa803"},{"key":"16_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"A Torres","year":"2017","unstructured":"Torres A, Chastre J, Ewig S et al (2017) International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. Eur Respir J 50:1\u201326. https:\/\/doi.org\/10.1183\/13993003.00582-2017","journal-title":"Eur Respir J"},{"key":"16_CR118","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP et al (2019) International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacother J Hum Pharmacol Drug Ther 39:10\u201339. https:\/\/doi.org\/10.1002\/phar.2209","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"16_CR119","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s00134-013-2828-9","volume":"39","author":"M Tumbarello","year":"2013","unstructured":"Tumbarello M, de Pascale G, Trecarichi EM et al (2013) Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med 39:682\u2013692. https:\/\/doi.org\/10.1007\/s00134-013-2828-9","journal-title":"Intensive Care Med"},{"key":"16_CR120","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/ccm.0000000000000771","volume":"43","author":"A Valachis","year":"2015","unstructured":"Valachis A, Samonis G, Kofteridis DP (2015) The role of aerosolized colistin in the treatment of ventilator-associated pneumonia. Crit Care Med 43:527\u2013533. https:\/\/doi.org\/10.1097\/ccm.0000000000000771","journal-title":"Crit Care Med"},{"key":"16_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s1473-3099(17)30615-1","volume":"18","author":"KZ Vardakas","year":"2017","unstructured":"Vardakas KZ, Voulgaris GL, Maliaros A et al (2017) Prolonged versus short-term intravenous infusion of antipseudomonal \u00ce2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis 18:1\u201313. https:\/\/doi.org\/10.1016\/s1473-3099(17)30615-1","journal-title":"Lancet Infect Dis"},{"key":"16_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2017.05.016","volume":"51","author":"KZ Vardakas","year":"2018","unstructured":"Vardakas KZ, Voulgaris GL, Samonis G, Falagas ME (2018) Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis. Int J Antimicrob Ag 51:1\u20139. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.05.016","journal-title":"Int J Antimicrob Ag"},{"key":"16_CR123","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/antibiotics9020071","volume":"9","author":"A Vena","year":"2020","unstructured":"Vena A, Giacobbe DR, Castaldo N et al (2020) Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant Gram-negative bacteria other than carbapenem-resistant Enterobacterales. Antibiotics 9:71. https:\/\/doi.org\/10.3390\/antibiotics9020071","journal-title":"Antibiotics"},{"key":"16_CR124","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1128\/aac.02744-13","volume":"58","author":"A Walkty","year":"2014","unstructured":"Walkty A, Adam H, Baxter M et al (2014) In vitro activity of plazomicin against 5,015 Gram-negative and Gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011\u20132012. Antimicrob Agents Chemother 58:2554\u20132563. https:\/\/doi.org\/10.1128\/aac.02744-13","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR125","doi-asserted-by":"publisher","DOI":"10.1177\/20420986211027096","volume":"12","author":"L-T Wang","year":"2021","unstructured":"Wang L-T, Lin W-T, Lai C-C et al (2021) The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis. Ther Adv Drug Saf 12:204209862110270. https:\/\/doi.org\/10.1177\/20420986211027096","journal-title":"Ther Adv Drug Saf"},{"key":"16_CR126","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ajic.2015.01.028","volume":"43","author":"BJ Werth","year":"2015","unstructured":"Werth BJ, Carreno JJ, Reveles KR (2015) Shifting trends in the incidence of Pseudomonas aeruginosa septicemia in hospitalized adults in the United States from 1996\u20132010. Am J Infect Control 43:465\u2013468. https:\/\/doi.org\/10.1016\/j.ajic.2015.01.028","journal-title":"Am J Infect Control"},{"key":"16_CR127","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.tim.2016.01.008","volume":"24","author":"C Winstanley","year":"2016","unstructured":"Winstanley C, O\u2019Brien S, Brockhurst MA (2016) Pseudomonas aeruginosa evolutionary adaptation and diversification in cystic fibrosis chronic lung infections. Trends Microbiol 24:327\u2013337. https:\/\/doi.org\/10.1016\/j.tim.2016.01.008","journal-title":"Trends Microbiol"},{"key":"16_CR128","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijantimicag.2017.11.009","volume":"51","author":"SD Winter","year":"2018","unstructured":"Winter SD, Wauters J, Meersseman W et al (2018) Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial. Int J Antimicrob Ag 51:562\u2013570. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.11.009","journal-title":"Int J Antimicrob Ag"},{"key":"16_CR129","doi-asserted-by":"publisher","first-page":"e02323-17","DOI":"10.1128\/aac.02323-17","volume":"62","author":"J Wu","year":"2018","unstructured":"Wu J, Racine F, Wismer MK et al (2018) Exploring the pharmacokinetic\/pharmacodynamic relationship of relebactam (MK-7655) in combination with imipenem in a hollow-fiber infection model. Antimicrob Agents Chemother 62:e02323-17. https:\/\/doi.org\/10.1128\/aac.02323-17","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR130","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/s1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M et al (2021) Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 21:213\u2013225. https:\/\/doi.org\/10.1016\/s1473-3099(20)30731-3","journal-title":"Lancet Infect Dis"},{"key":"16_CR131","doi-asserted-by":"publisher","unstructured":"Yahav D, Giske CG, Gr\u0101matniece A et al (2020) New \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations. Clin Microbiol Rev 34. https:\/\/doi.org\/10.1128\/cmr.00115-20","DOI":"10.1128\/cmr.00115-20"},{"key":"16_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diagmicrobio.2016.10.008","volume":"87","author":"YK Yoon","year":"2016","unstructured":"Yoon YK, Kim HA, Ryu SY et al (2016) Tree-structured survival analysis of patients with Pseudomonas aeruginosa bacteremia: a multicenter observational cohort study. Diagn Microbiol Infect Dis 87:1\u20138. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.10.008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"16_CR133","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1093\/jac\/dkz245","volume":"74","author":"E-J Yoon","year":"2019","unstructured":"Yoon E-J, Kim D, Lee H et al (2019) Mortality dynamics of Pseudomonas aeruginosa bloodstream infections and the influence of defective OprD on mortality: prospective observational study. J Antimicrob Chemother 74:2774\u20132783. https:\/\/doi.org\/10.1093\/jac\/dkz245","journal-title":"J Antimicrob Chemother"},{"key":"16_CR134","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12866-019-1522-7","volume":"19","author":"K Young","year":"2019","unstructured":"Young K, Painter RE, Raghoobar SL et al (2019) In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. BMC Microbiol 19:150. https:\/\/doi.org\/10.1186\/s12866-019-1522-7","journal-title":"BMC Microbiol"},{"key":"16_CR135","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1093\/jac\/dkaa217","volume":"75","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhao C, Wang Q et al (2020) Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli. J Antimicrob Chemother 75:2609\u20132615. https:\/\/doi.org\/10.1093\/jac\/dkaa217","journal-title":"J Antimicrob Chemother"},{"key":"16_CR136","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ijantimicag.2018.07.004","volume":"52","author":"H Zhong","year":"2018","unstructured":"Zhong H, Zhao X-Y, Zhang Z-L et al (2018) Evaluation of the efficacy and safety of ceftazidime\/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis. Int J Antimicrob Ag 52:443\u2013450. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.07.004","journal-title":"Int J Antimicrob Ag"},{"key":"16_CR137","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40266-016-0431-9","volume":"34","author":"Q-T Zhou","year":"2017","unstructured":"Zhou Q-T, He B, Shen N et al (2017) Meropenem dosing based on a population pharmacokinetic \u2013 pharmacodynamic model in elderly patients with infection of the lower respiratory tract. Drugs Aging 34:115\u2013121. https:\/\/doi.org\/10.1007\/s40266-016-0431-9","journal-title":"Drugs Aging"},{"key":"16_CR138","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/microorganisms9061154","volume":"9","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Monsel A, Roberts JA et al (2021) Nebulized colistin in ventilator-associated pneumonia and tracheobronchitis: historical background, pharmacokinetics and perspectives. Microorganisms 9:1154. https:\/\/doi.org\/10.3390\/microorganisms9061154","journal-title":"Microorganisms"}],"container-title":["Advances in Experimental Medicine and Biology","Pseudomonas aeruginosa"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-08491-1_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T19:06:00Z","timestamp":1666119960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-08491-1_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783031084904","9783031084911"],"references-count":138,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-08491-1_16","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"19 October 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}